Posts
Welcome to the Fritsma Factor, please join our hemostasis discussions.
A recent 2020 Clinical Laboratory Science Journal, publication of the American Society for Clinical...
Dec 21, 2020 6:52pm
Our December, 2020 Quick Question addresses the uncommon incidence of breakthrough bleeds in...
Dec 1, 2020 5:30pm
Our November, 2020 Quick Question attracted 37 participants. Here is the stem: "Which VWF activity...
Dec 1, 2020 5:19pm
Here is a comprehensive review of the 2017 hemophilia A therapeutic emicizumab [HEMLIBRA]. The...
Nov 29, 2020 9:52am
Dec 21, 2020 6:52pm
A recent 2020 Clinical Laboratory Science Journal, publication of the American Society for Clinical Laboratory Science, offers the following hemostasis-related articles, purchasable for $5 each:
0 Comments
Dec 1, 2020 5:30pm
Our December, 2020 Quick Question addresses the uncommon incidence of breakthrough bleeds in hemophilia A patient who are being treated with emicizumab [HEMLIBRA], the immunotherapeutic that bypasses factor VIII. Treatment may become an issue in severe hemophilia in which patients develop inhibitors.
0 Comments
Dec 1, 2020 5:19pm
Our November, 2020 Quick Question attracted 37 participants. Here is the stem: "Which VWF
activity assay is preferred at
your facility [check 10-31-20 post]?" The selections were...
0 Comments
Nov 29, 2020 9:52am
Here is a comprehensive review of the 2017 hemophilia A therapeutic emicizumab [HEMLIBRA]. The author, Michael A. Nardi, MD, NYU Langone Health, details the effects of emicizumab on standard clot-based laboratory assays and the need for chromogenic substrate test methods.
0 Comments
